Engineered T-cell activating fusion protein

Engineered T-cell activating fusion proteins are synthetic molecules created by fusing key functional domains from different immune signaling or antibody proteins to modulate T-cell activation for therapeutic benefit. These fusion proteins can combine, for example, an extracellular domain from an inhibitory or tumor-targeting receptor with an intracellular co-stimulatory or pro-survival signaling domain, enabling redirected or enhanced T-cell activity against cancer or other diseases. Examples include Fas-4-1BB fusion proteins (which convert inhibitory Fas signals to survival/activation signals), T-cell receptor fusion constructs (TRuCs) where antibody-based domains are linked to TCR subunits for antigen recognition, and T-cell antigen couplers (TACs) that channel activation signal through the endogenous TCR pathway. These constructs are at the forefront of next-generation cell therapy designs, offering improved specificity and function but also presenting unique challenges for clinical management and safety[1][2][3][4].

Other names

Immunomodulatory fusion proteinT-cell receptor fusion construct (TRuC)Fas-4-1BB fusion proteinT-cell antigen coupler (TAC)chimeric fusion protein for T-cell activationengineered TCR fusion protein

Artificial induction of T-cell activation through engineered intracellular signaling (costimulatory or survival domains), bypassing or augmenting physiological receptor pathways[1][2][3][4]